(lp0
S'Peregrine Pharma  Says Five Abstracts Accepted for Presentation at AACR StreetInsider.com - Mar 23, 2017 Peregrine Pharmaceuticals, Inc.   today announced that four preclinical abstracts and one clinical abstract have been accepted for presentation at the Annual Meeting of the American Association for Cancer Research&nbsp;...'
p1
aS"Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of ... GlobeNewswire  - Mar 13, 2017 TUSTIN, Calif., March 13, 2017  -- Peregrine Pharmaceuticals, Inc.  , a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and&nbsp;...Peregrine Pharmaceuticals : What's Next? - Insider FinancialPeregrine Pharmaceuticals'  CEO Steve King on Q3 2017 Results - Earnings ... - Seeking Alpha"
p2
aS"Today Analysts Focus on Peregrine Pharmaceuticals, Inc. , Walter ... StockNewsJournal - 20 hours ago Investors who are keeping close eye on the stock of Peregrine Pharmaceuticals, Inc.  established that the company was able to keep return on investment at -68.06 in the trailing twelve month while Reuters data showed that industry's&nbsp;..."
p3
aS'Peregrine Pharmaceuticals  Anticipates Avid Revenue In Range Of ... StockNewsUnion - 20 hours ago Peregrine Pharmaceuticals  released their financial report for Q3 2017, and gave an update on its contract manufacturing segment, clinical and preclinical pipeline.Short Interest in Peregrine Pharmaceuticals  Declines By 40.5% - Chaffey BreezePeregrine Pharmaceuticals, Inc.  Closed the Last Trading Session with ... - The Newburgh Press'
p4
aS"Today's Research Reports on Trending Biotech Tickers: Peregrine ... Yahoo Finance - Mar 9, 2017 Peregrine Pharmaceuticals' shares declined 1.86 percent to close at $0.68 a share on Wednesday. The stock traded between $0.65 and $0.69 on volume of 3.18 million shares traded."
p5
aS"BRIEF-Peregrine Pharmaceuticals Q3 loss per share $0.04 Reuters - Mar 13, 2017 Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news&nbsp;..."
p6
aS'Ronin Capital Shows New 6.8% Stake in Peregrine Pharmaceuticals  - 13D StreetInsider.com - Mar 2, 2017 Stephen White is the indirect beneficial owner of all of the securities of Peregrine Pharmaceuticals, Inc. held of record or beneficially owned by SW Investment Management LLC by virtue of his having sole voting and dispositive power over such shares.Most Active Stock Update: Peregrine Pharmaceuticals, Inc.  - HugoPressInvestor Research Report on Peregrine Pharmaceuticals, Inc.  - FactsReporter'
p7
aS"PEREGRINE PHARMACEUTICALS, INC.  Files An 8-K Other Events Market Exclusive - Mar 9, 2017 Peregrine Pharmaceuticals, Inc.  is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which&nbsp;...Analyst's Predictions on Tidewater Inc. , Peregrine Pharmaceuticals, Inc ... - StockNewsJournal"
p8
aS'Peregrine Pharmaceuticals  Is One To Watch Ahead Of Earnings Insider Financial - Mar 6, 2017 Our more regular readers will know that Peregrine Pharmaceuticals  is one of the stocks we visit regularly. The company - as we have stated in the past, and an opinion that still stands - is one of the most mis-valued/misunderstood ...Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2017 ... - GlobeNewswire Peregrine Pharmaceuticals, Inc.  hit its 52 Week low of $0.28 on ... - The Newburgh Press'
p9
aS"Biotech Industry Continues to Provide Investors with Gains in 2017: Today's ... Yahoo Finance - Mar 27, 2017 NEW YORK, NY / ACCESSWIRE / March 27, 2017 / Peregrine Pharmaceuticals' shares might be trading below the dollar mark, but the upward trend has been promising."
p10
a.